View in EDS

SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab.

Saved in:
Bibliographic Details
Title: SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab.
Authors: Kolkıran, Nagihan, Erdoğan, Atike Pınar, Şahbazlar, Mustafa, Taş, Semra, Gököz Doğu, Gamze, Canaslan, Kübra, Ünek, İlkay Tuğba, Demirkıran, Özge, Demir, Bilgin, Teküstün, Güler Nur, Tanrıverdi, Özgür, Ekinci, Ferhat
Source: Current Oncology; Oct2025, Vol. 32 Issue 10, p566, 17p
Subject Terms: NON-small-cell lung carcinoma, NIVOLUMAB, BIOMARKERS, SURVIVAL rate, INFLAMMATION, IMMUNOTHERAPY, PROGNOSIS
Abstract: Simple Summary: Despite the success of immunotherapy with nivolumab in advanced non-small cell lung cancer, many patients still experience poor outcomes. Reliable tools are needed to better predict which patients are most likely to benefit from treatment. This study introduces SUVmax-IPI, a novel and practical biomarker that combines two routinely assessed parameters: tumor metabolic activity and systemic inflammation. It aimed to predict survival outcomes in patients with metastatic non-small cell lung cancer receiving nivolumab. By integrating positron emission tomography imaging and standard laboratory tests, this score provides a simple and cost-effective tool for clinicians to better identify patients at higher risk of poor outcomes. SUVmax-IPI can help guide treatment decisions, improve patient counseling, and enhance personalized care in the immunotherapy setting. Background/Objectives: Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need. To address this gap, we developed the SUVmax-IPI, a novel prognostic index combining maximum standardized uptake value (SUVmax) from 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) with systemic inflammatory markers. This study aimed to evaluate the prognostic value of SUVmax-IPI in patients with NSCLC receiving nivolumab therapy. Methods: This multicenter retrospective analysis included 187 patients with metastatic NSCLC receiving nivolumab across 5 tertiary institutions. The SUVmax-IPI incorporated pretreatment SUVmax and laboratory-based inflammatory prognostic index (IPI) parameters. Survival outcomes were evaluated using Kaplan–Meier analysis with log-rank testing and multivariate cox regression. Results: Receiver operating characteristic (ROC) analysis established an optimal SUVmax-IPI cut-off of 241.9. Patients with SUVmax-IPI ≤ 241.9 had significantly better survival outcomes: median overall survival (OS) was 35 versus 15 months (p = 0.002). For progression-free survival (PFS), although a numerical difference favored patients with SUVmax-IPI ≤ 241.9 (median: 15 vs. 8 months), this did not reach statistical significance (log-rank p = 0.175). Multivariate analysis confirmed SUVmax-IPI as an independent predictor of survival (p = 0.002). Conclusions: The SUVmax-IPI represents a promising prognostic tool for patients with metastatic NSCLC who received at least 3 months of nivolumab, integrating metabolic and inflammatory parameters to predict survival outcomes. [ABSTRACT FROM AUTHOR]
Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Description
Abstract:Simple Summary: Despite the success of immunotherapy with nivolumab in advanced non-small cell lung cancer, many patients still experience poor outcomes. Reliable tools are needed to better predict which patients are most likely to benefit from treatment. This study introduces SUVmax-IPI, a novel and practical biomarker that combines two routinely assessed parameters: tumor metabolic activity and systemic inflammation. It aimed to predict survival outcomes in patients with metastatic non-small cell lung cancer receiving nivolumab. By integrating positron emission tomography imaging and standard laboratory tests, this score provides a simple and cost-effective tool for clinicians to better identify patients at higher risk of poor outcomes. SUVmax-IPI can help guide treatment decisions, improve patient counseling, and enhance personalized care in the immunotherapy setting. Background/Objectives: Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need. To address this gap, we developed the SUVmax-IPI, a novel prognostic index combining maximum standardized uptake value (SUVmax) from <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) with systemic inflammatory markers. This study aimed to evaluate the prognostic value of SUVmax-IPI in patients with NSCLC receiving nivolumab therapy. Methods: This multicenter retrospective analysis included 187 patients with metastatic NSCLC receiving nivolumab across 5 tertiary institutions. The SUVmax-IPI incorporated pretreatment SUVmax and laboratory-based inflammatory prognostic index (IPI) parameters. Survival outcomes were evaluated using Kaplan–Meier analysis with log-rank testing and multivariate cox regression. Results: Receiver operating characteristic (ROC) analysis established an optimal SUVmax-IPI cut-off of 241.9. Patients with SUVmax-IPI ≤ 241.9 had significantly better survival outcomes: median overall survival (OS) was 35 versus 15 months (p = 0.002). For progression-free survival (PFS), although a numerical difference favored patients with SUVmax-IPI ≤ 241.9 (median: 15 vs. 8 months), this did not reach statistical significance (log-rank p = 0.175). Multivariate analysis confirmed SUVmax-IPI as an independent predictor of survival (p = 0.002). Conclusions: The SUVmax-IPI represents a promising prognostic tool for patients with metastatic NSCLC who received at least 3 months of nivolumab, integrating metabolic and inflammatory parameters to predict survival outcomes. [ABSTRACT FROM AUTHOR]
ISSN:11980052
DOI:10.3390/curroncol32100566